59 completed, 18 terminated, 12 recruiting, 9 active not recruiting. 79 Phase 2, 24 Phase 1, 20 Phase 3, 3 Phase 4.
Follow cabazitaxel: new trials by email Literature Review of cabazitaxel trials Research Report on cabazitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Amgen | 750 | 2025-11-28 | 2026-10-20 |
| Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer Cabazitaxel and carboplatin, Lu-PSMA-617 - Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 44 | 2025-07-14 | 2026-10-02 |
| A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel - Metastatic Castration-resistant Prostate Cancer, MCRPC | Phase 2 | Not yet recruiting | Jina Pharmaceuticals Inc. | 75 | 2025-05-01 | 2025-03-24 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) Xaluritamig, Abiraterone, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Amgen | 707 | 2024-12-09 | 2026-05-15 |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body Biospecimen Collection, Bone Scan, Cabazitaxel - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 3 | Recruiting | SWOG Cancer Research Network | 528 | 2024-11-27 | 2026-01-22 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-21 |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) ADI-PEG 20, Cabazitaxel, Carboplatin - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-02-29 | 2026-09-18 |
| Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC Darolutamide, Docetaxel or cabazitaxel - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Erasmus Medical Center | 245 | 2023-11-29 | 2026-09-10 |
| Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) Pembrolizumab, Carboplatin, Cabazitaxel - Prostate Cancer Metastatic | Phase 2 | Recruiting | Fundacion Oncosur | 42 | 2023-05-05 | 2024-06-11 |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer Pasritamig, Cetrelimab, Cabazitaxel - Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer | Phase 1 | Recruiting | Janssen Research & Development, LLC | 300 | 2023-04-26 | 2026-09-25 |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland abiraterone, enzalutamide, docetaxel - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Pfizer | 1083 | 2023-02-13 | 2026-01-29 | |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer Cabazitaxel, 177Lu-PSMA-617 - Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 35 | 2022-07-14 | 2025-04-06 |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Completed | Xencor, Inc. | 72 | 2021-10-22 | 2026-05-05 |
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Nivolumab, Ipilimumab, Carboplatin - Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | Andrew J. Armstrong, MD | 41 | 2021-06-07 | 2026-04-06 |
| Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome Cabazitaxel - Prostate Cancer | Phase 2 | Unknown | The Clatterbridge Cancer Centre NHS Foundation Trust | 120 | 2021-01-15 | 2021-01-05 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. AZD4635, Durvalumab, Cabazitaxel - Progressive Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Completed | AstraZeneca | 30 | 2020-08-04 | 2023-08-09 |
Showing 20 of 114. Sign in to see all of them.
Prostatic Neoplasms (54) · Neoplasm Metastasis (11) · Neoplasms (8) · Recurrence (7) · Breast Neoplasms (5) · Carcinoma, Transitional Cell (4) · Brain Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Neoplastic Cells, Circulating (3) · Stomach Neoplasms (3) · Carcinoma, Squamous Cell (2) · Glioblastoma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms, Castration-Resistant (2) · Squamous Cell Carcinoma of Head and Neck (2)
Sanofi (18) · M.D. Anderson Cancer Center (6) · Erasmus Medical Center (3) · UNICANCER (3) · University Hospitals Bristol and Weston NHS Foundation Trust (3) · Achieve Life Sciences (2) · Amgen (2) · AstraZeneca (2) · Case Comprehensive Cancer Center (2) · ECOG-ACRIN Cancer Research Group (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Hellenic Cooperative Oncology Group (2) · OHSU Knight Cancer Institute (2) · SCRI Development Innovations, LLC (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2)
United States (57) · France (22) · Spain (19) · Canada (18) · Italy (15) · United Kingdom (15) · Germany (14) · Australia (13) · Belgium (13) · Netherlands (12) · Denmark (10) · Sweden (10) · Poland (8) · South Korea (8) · Taiwan (8)
Amit K Bahl (2) · Ana Aparicio (2) · Paul Corn (2) · Ahmad Awada, MD, PhD (1) · Albert Font Pous, Dr (1) · Alfredo Berruti, MD (1) · Amit Bahl (1) · Ana Aparicio, MD (1) · Ana M. Aparicio, MD (1)
PMID 42020286, PMID 23228299, PMID 29500065, PMID 33740734, PMID 16172198, PMID 16172456, PMID 1675220, PMID 18491247, PMID 18764725, PMID 20888992, PMID 21718784, PMID 21883349, PMID 22156929, PMID 22189997, PMID 22344233, PMID 22551107, PMID 22743148, PMID 23091116, PMID 23370353, PMID 23723295, PMID 24099585, PMID 24722180, PMID 25001524, PMID 25117475, PMID 25538172, PMID 25639506, PMID 25809824, PMID 26200278, PMID 2702835, PMID 27903924, PMID 28419193, PMID 28632486, PMID 28753384, PMID 28809610, PMID 29033099, PMID 29678476, PMID 30301829, PMID 30537991, PMID 31329922, PMID 31515154, PMID 31566937, PMID 31595044, PMID 32586393, PMID 32916128, PMID 32926841, PMID 33463373, PMID 33581798, PMID 33727028, PMID 33836265, PMID 34274136
2014 (3), 2016 (2), U10CA180820 (2), 2009 (1), 2023 (1), P30CA016672 (1), U10CA180888 (1)